gip glp 1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Dual and Triple Gut Peptide
Description
GIP enhances insulin secretion and affects fat metabolism
April 2019
Abstract Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications
However, the peptide is degraded by the enzymes DPP-IV and neutral endopeptidase 24.11 (Holst, 2007)
Indianapolis, Indiana: Eli Lilly & Co
GLP-1 inhibits PKC2 phosphorylation to improve the osteogenic differentiation potential of hPDLSCs in the AGE microenvironment
